HTG Molecular Diagnostics (NASDAQ:HTGM) (Tucson, Ariz.), a provider of instruments and reagents for molecular profiling applications, has joined the Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine as an official technology partner.
WIN represents a global collaboration of cancer centers, life science and biotech organizations, pharmaceutical and technology companies, academic institutions, health plans, and patient advocacy groups.
These stakeholders have come together to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual's tumor and accounting for genetic differences across diverse populations.
WIN will use the HTG EdgeSeq system and products for lung cancer research and clinical trial investigations aimed to develop gene expression molecular profiling in vitro diagnostic tests for multiple targeted therapies. HTG EdgeSeq technology will enable WIN members to measure quantitative expression of both message (mRNA) and microRNA
(miRNA) from very small, challenging sample types such as formalin-fixed, paraffin-embedded (FFPE) tissues and plasma from blood.